Form 4: Vor Biopharma Director, Joshua Resnick, Granted Stock Options

Director Joshua Resnick received stock options for 30,000 shares of Vor Biopharma Inc. (VOR) common stock.

Summary

• Joshua Resnick, a director of Vor Biopharma Inc., was granted stock options to purchase 30,000 shares of common stock on May 23, 2024.
• The exercise price of the options is $1.61 per share.
• The options vest on the earlier of May 23, 2025, or the next annual meeting of stockholders, contingent upon continued service as a director.
• The options expire on May 22, 2034.
• Resnick holds the option for the benefit of RA Capital Healthcare Fund, L.P. and the RA Capital Nexus Fund, L.P., and will turn over any proceeds to offset advisory fees.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. The sentiment is slightly positive as it indicates alignment of director interests with shareholders.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and value creation.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotech industry, to align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to board members are a common practice in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options as part of their director compensation packages.
• The size of the grant (30,000 shares) would need to be compared to the overall compensation structure and market capitalization of Vor Biopharma to determine if it is in line with industry standards.

Related Party Transactions

• The Reporting Person's arrangement with RA Capital Management, L.P. (the 'Adviser'), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the 'Fund') and the RA Capital Nexus Fund, L.P. (the 'Nexus Fund').
• The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The impact on employees is likely minimal, as this is a standard compensation practice for board members.

Key Dates